Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.24 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1664
    +0.0012 (+0.10%)
     

  • GBP/USD

    1.2563
    +0.0016 (+0.13%)
     

  • Bitcoin GBP

    50,180.71
    -764.27 (-1.50%)
     

  • CMC Crypto 200

    1,362.74
    +50.11 (+3.82%)
     

  • S&P 500

    5,166.52
    +38.73 (+0.76%)
     

  • DOW

    38,764.65
    +88.97 (+0.23%)
     

  • CRUDE OIL

    78.70
    +0.59 (+0.76%)
     

  • GOLD FUTURES

    2,335.00
    +26.40 (+1.14%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

  • HANG SENG

    18,578.30
    +102.38 (+0.55%)
     

  • DAX

    18,175.21
    +173.61 (+0.96%)
     

  • CAC 40

    7,996.64
    +39.07 (+0.49%)
     

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

Akoya Biosciences, Inc.
·1-min read
Akoya Biosciences, Inc.
Akoya Biosciences, Inc.

MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
investors@akoyabio.com

Media Contact:
Christine Quern
media@akoyabio.com